PAVmed, Inc. (PAVM)

PAVmed's stock has been influenced by several events including the Q3 2025 earnings report where, despite exceeding expectations, shares declined. Lucid Diagnostics' business update highlighted revenue and a public offering. Lucid Diagnostics was also recognized as a top workplace. PAVmed announced a reverse stock split and Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract, causing the stock to surge. PAVmed closed financings, eliminating convertible securities. Analysts increased the price target, and the stock has exhibited high volatility.

Information on demand seasonality for PAVmed Inc.'s products is not explicitly available. Demand is likely driven by disease prevalence, screening guidelines, healthcare policy, reimbursement, adoption by healthcare providers, cancer treatment cycles, and new product launches. Medical diagnostics and devices for serious conditions tend to have stable demand, influenced by medical advancements, regulatory approvals, and healthcare system adoption.

PAVmed Inc. is a diversified, commercial-stage medical technology company focused on developing and commercializing innovative medical solutions. It operates within the healthcare and medical device industry, focusing on medical devices, diagnostics, and digital health. PAVmed functions as a holding company, advancing medical technologies through independently financed subsidiaries using a central shared services model. Key products include EsoGuard, EsoCheck, Veris Cancer Care Platform, CarpX, EsoCure, PortIO, NextCath, NextFlo, and Caldus.

PAVmed Inc. is headquartered in New York City and primarily focuses on acquiring, developing, and commercializing products for unmet needs in the United States. While its primary operations are in the U.S., its stock is traded internationally.

PAVmed's brand reputation is tied to the progress of its subsidiaries, Lucid Diagnostics and Veris Health. Positive developments include expert support for Medicare coverage of EsoGuard, a U.S. Department of Veterans Affairs contract for EsoGuard, the commercial launch of the Veris Cancer Care Platform, and industry recognition for Lucid Diagnostics. Challenges include concerns about financial instability, Nasdaq compliance issues, and underperformance against the market and industry.

PAVmed Inc. is publicly traded on the Nasdaq Capital Market with significant insider ownership (50.74%), indicating substantial control by the leadership team. Ira Scott Greenspan is a major individual shareholder with 24.09% ownership. Institutional ownership is relatively low at 4.95%, with key institutional owners including First Manhattan Co and Vanguard Group Inc.